Evidence map›Paper›PMID 19934299›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009

Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.

Emily K Mader, Yoshihiro Maeyama, Yi Lin, Greg W Butler, Holly M Russell, Evanthia Galanis, Stephen J Russell, Allan B Dietz, Kah-Whye Peng

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 204 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.International journal of molecular sciences · 2024
    Review
  20. Review

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Emily K MaderDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Yoshihiro Maeyama
Yi Lin
Greg W Butler
Holly M Russell
Evanthia Galanis
Stephen J Russell
Allan B Dietz
Kah-Whye Peng
Mayo Clinic · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Antibody Neutralization of Therapeutic VirusesR01CA129966 · NCI · MAYO CLINIC ROCHESTER · PI RUSSELL, STEPHEN J · 2008 to 2012
$2.5M
Optimizing Measles Virotherapy in the Treatment of Ovarian CancerR01CA136547 · NCI · MAYO CLINIC ROCHESTER · PI GALANIS, EVANTHIA, PENG, KAH-WHYE · 2009 to 2012
$2.0M
NCI NIH HHS CA129966NCI NIH HHS CA136547NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA129966NCI NIH HHS R01 CA136547
6 · The paper itself

Abstract

purposePreexisting antiviral antibodies in cancer patients can quickly neutralize oncolytic measles virus (MV) and decrease its antitumor potency. In contrast to "naked" viruses, cell-associated viruses are protected from antibody neutralization. Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used. EXPERIMENTAL

designAntimeasles antibodies titers in ovarian cancer patients were determined. The protection of MV by MSC from antimeasles antibodies, the in vivo biodistribution profiles, and tumor infiltration capability of MSC were determined. Measles-naïve or immune tumor-bearing mice were treated with naked virus or MSC-associated virus and mice survivals were compared.

resultsMSC transferred MV infection to target cells via cell-to-cell heterofusion and induced syncytia formation in the presence of high titers of antimeasles antibody, at levels that completely inactivated naked virus. Athymic mice bearing i.p. human SKOV3ip.1 ovarian tumor xenografts passively immunized with measles-immune human serum were treated with saline, naked MV, or MV-infected MSC. Bioluminescent and fluorescent imaging data indicated that i.p. administered MSC localized to peritoneal tumors, infiltrated into the tumor parenchyma, and transferred virus infection to tumors in measles naïve and passively immunized mice. Survival of the measles-immune mice was significantly enhanced by treatment with MV-infected MSC. In contrast, survivals of passively immunized mice were not prolonged by treatment with naked virus or uninfected MSC.

conclusionsMSC should be used as carriers of MV for intraperitoneal virotherapy in measles-immune ovarian cancer patients.

Indexed as

AnimalsCancer VaccinesCell Line, TumorChlorocebus aethiopsFemaleHumansImmunoglobulin GMeasles virusMesenchymal Stem CellsMiceMice, NudeOncolytic VirotherapyOncolytic VirusesOvarian NeoplasmsVero CellsCancer VaccinesImmunoglobulin G

Identifiers

PMID19934299
PMCPMC2787715
OpenAlexW2137322846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.